FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2920559179> ?p ?o ?g. }

• W2920559179 endingPage "915" @default.
• W2920559179 startingPage "896" @default.
• W2920559179 abstract "Little is known about real-world use of small molecule kinase inhibitors (SMKI) for advanced thyroid cancer in the United States. This study examined prescribing patterns of SMKI agents recommended by the National Comprehensive Cancer Center (NCCN). This retrospective study used a national health insurance database to identify patients diagnosed with thyroid cancer during 1/1/2006–6/30/2016 and with prescription claims for NCCN-recommended SMKI during 1/1/2010–5/31/2016 whose first claim date was the index date. Inclusion also required continuous enrollment in a health plan for 3 months pre-index (baseline) and ≥ 1 month post-index (follow-up) with no claims for SMKI during baseline. Lines of therapy (LOT) were defined by the date of SMKI claims and days of drug supply. Median time to SMKI discontinuation in each LOT was estimated by Kaplan–Meier method. The study included 217 patients. During follow-up (mean duration 499.0 days), 35.5% of patients (n = 77) received a second or later LOT; among patients with ≥ 12 months follow-up after first LOT (LOT1) initiation, 53.1% (n = 60) received a second or later LOT. Median treatment duration was 5.0 months for LOT1 and 5.1 months for LOT2. Over the entire follow-up period (2010–2016), sorafenib was the most common regimen in LOT1 (36.9% of patients) and LOT2 (24.7%) followed by sunitinib and levantinib (13.4% each) in LOT1 and sunitinib (19.5%) in LOT2. Starting in 2015, the year lenvatinib was approved for differentiated thyroid cancer, lenvatinib was the most common first-line regimen among patients initiating LOT1 in 2015 (43.4%) and 2016 (66.7%). Sorafenib was the most common first-line agent during 2010–2014 but was supplanted by lenvatinib starting in 2015. Approximately 36–53% of patients received a second-line treatment. Median treatment duration results suggested potential benefit of SMKI in second-line therapy. SMKI treatment after first-line failure may be considered for appropriately selected patients. Eisai, Inc. (Woodcliff Lake, NJ)." @default.
• W2920559179 created "2019-03-11" @default.
• W2920559179 creator A5007598937 @default.
• W2920559179 creator A5014595568 @default.
• W2920559179 creator A5022036818 @default.
• W2920559179 creator A5032563546 @default.
• W2920559179 creator A5054804176 @default.
• W2920559179 creator A5071060850 @default.
• W2920559179 date "2019-02-28" @default.
• W2920559179 modified "2023-10-05" @default.
• W2920559179 title "Real-World Treatment Patterns Among Patients Initiating Small Molecule Kinase Inhibitor Therapies for Thyroid Cancer in the United States" @default.
• W2920559179 cites W1967792499 @default.
• W2920559179 cites W1968812902 @default.
• W2920559179 cites W1990171304 @default.
• W2920559179 cites W2008147728 @default.
• W2920559179 cites W2028156774 @default.
• W2920559179 cites W2035106853 @default.
• W2920559179 cites W2040642592 @default.
• W2920559179 cites W2046063618 @default.
• W2920559179 cites W2049546347 @default.
• W2920559179 cites W2074048861 @default.
• W2920559179 cites W2079353352 @default.
• W2920559179 cites W2089971534 @default.
• W2920559179 cites W2100969445 @default.
• W2920559179 cites W2118988113 @default.
• W2920559179 cites W2119501407 @default.
• W2920559179 cites W2121656227 @default.
• W2920559179 cites W2123054968 @default.
• W2920559179 cites W2123947456 @default.
• W2920559179 cites W2129453496 @default.
• W2920559179 cites W2138194420 @default.
• W2920559179 cites W2145150141 @default.
• W2920559179 cites W2158801409 @default.
• W2920559179 cites W2168076926 @default.
• W2920559179 cites W2182110379 @default.
• W2920559179 cites W2337147455 @default.
• W2920559179 cites W2346719010 @default.
• W2920559179 cites W2570618306 @default.
• W2920559179 cites W2603577764 @default.
• W2920559179 cites W2890867692 @default.
• W2920559179 doi "https://doi.org/10.1007/s12325-019-0890-6" @default.
• W2920559179 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6824453" @default.
• W2920559179 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30820872" @default.
• W2920559179 hasPublicationYear "2019" @default.
• W2920559179 type Work @default.
• W2920559179 sameAs 2920559179 @default.
• W2920559179 citedByCount "15" @default.
• W2920559179 countsByYear W29205591792020 @default.
• W2920559179 countsByYear W29205591792021 @default.
• W2920559179 countsByYear W29205591792022 @default.
• W2920559179 countsByYear W29205591792023 @default.
• W2920559179 crossrefType "journal-article" @default.
• W2920559179 hasAuthorship W2920559179A5007598937 @default.
• W2920559179 hasAuthorship W2920559179A5014595568 @default.
• W2920559179 hasAuthorship W2920559179A5022036818 @default.
• W2920559179 hasAuthorship W2920559179A5032563546 @default.
• W2920559179 hasAuthorship W2920559179A5054804176 @default.
• W2920559179 hasAuthorship W2920559179A5071060850 @default.
• W2920559179 hasBestOaLocation W29205591791 @default.
• W2920559179 hasConcept C121608353 @default.
• W2920559179 hasConcept C126322002 @default.
• W2920559179 hasConcept C143998085 @default.
• W2920559179 hasConcept C167135981 @default.
• W2920559179 hasConcept C2426938 @default.
• W2920559179 hasConcept C2776264508 @default.
• W2920559179 hasConcept C2778019345 @default.
• W2920559179 hasConcept C2778695046 @default.
• W2920559179 hasConcept C2778715236 @default.
• W2920559179 hasConcept C2779490328 @default.
• W2920559179 hasConcept C2779761222 @default.
• W2920559179 hasConcept C2781413609 @default.
• W2920559179 hasConcept C71924100 @default.
• W2920559179 hasConcept C98274493 @default.
• W2920559179 hasConceptScore W2920559179C121608353 @default.
• W2920559179 hasConceptScore W2920559179C126322002 @default.
• W2920559179 hasConceptScore W2920559179C143998085 @default.
• W2920559179 hasConceptScore W2920559179C167135981 @default.
• W2920559179 hasConceptScore W2920559179C2426938 @default.
• W2920559179 hasConceptScore W2920559179C2776264508 @default.
• W2920559179 hasConceptScore W2920559179C2778019345 @default.
• W2920559179 hasConceptScore W2920559179C2778695046 @default.
• W2920559179 hasConceptScore W2920559179C2778715236 @default.
• W2920559179 hasConceptScore W2920559179C2779490328 @default.
• W2920559179 hasConceptScore W2920559179C2779761222 @default.
• W2920559179 hasConceptScore W2920559179C2781413609 @default.
• W2920559179 hasConceptScore W2920559179C71924100 @default.
• W2920559179 hasConceptScore W2920559179C98274493 @default.
• W2920559179 hasIssue "4" @default.
• W2920559179 hasLocation W29205591791 @default.
• W2920559179 hasLocation W29205591792 @default.
• W2920559179 hasLocation W29205591793 @default.
• W2920559179 hasOpenAccess W2920559179 @default.
• W2920559179 hasPrimaryLocation W29205591791 @default.
• W2920559179 hasRelatedWork W2036852888 @default.
• W2920559179 hasRelatedWork W2116758310 @default.
• W2920559179 hasRelatedWork W2339755730 @default.
• W2920559179 hasRelatedWork W2402089364 @default.
• W2920559179 hasRelatedWork W2433065005 @default.

• next